Teacher Retirement System of Texas Grows Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Teacher Retirement System of Texas boosted its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 22.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,192 shares of the company’s stock after buying an additional 2,782 shares during the period. Teacher Retirement System of Texas’ holdings in EyePoint Pharmaceuticals were worth $113,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of EYPT. Intech Investment Management LLC purchased a new position in shares of EyePoint Pharmaceuticals during the 3rd quarter worth $136,000. Charles Schwab Investment Management Inc. raised its holdings in shares of EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after buying an additional 7,967 shares during the period. Patient Square Capital LP purchased a new position in EyePoint Pharmaceuticals during the 3rd quarter valued at about $10,882,000. Wellington Management Group LLP grew its position in EyePoint Pharmaceuticals by 59.4% in the 3rd quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock valued at $1,372,000 after acquiring an additional 64,008 shares in the last quarter. Finally, Barclays PLC increased its stake in EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock worth $1,959,000 after buying an additional 197,033 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on EYPT shares. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Chardan Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Citigroup began coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Stock Up 6.3 %

Shares of NASDAQ EYPT opened at $5.37 on Thursday. The stock has a market cap of $369.07 million, a PE ratio of -2.69 and a beta of 1.41. EyePoint Pharmaceuticals, Inc. has a 52-week low of $4.92 and a 52-week high of $23.65. The business has a 50-day moving average price of $6.63 and a 200 day moving average price of $8.16.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. Sell-side analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.